A Study Evaluating TRIV-573 in Atopic Dermatitis

A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants With Moderate to Severe Atopic Dermatitis

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07782333

Enrollment

Registered

2026-08-24

Start date

2026-08-01

Completion date

2028-02-01

Last updated

2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573. Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo). The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.

Interventions

DRUGTRIV-573

TRIV-573 (Subcutaneous injection)

DRUGPlacebo

Placebo (Matching Placebo subcutaneous injection)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Has Atopic Dermatitis. * Has moderate to severe, active and symptomatic atopic dermatitis.

Exclusion criteria

* Severe or uncontrolled medical conditions. * Use of prohibited medications within stated washout periods.

Design outcomes

Primary

Measure	Time frame
Percentage of participants with improvement of AD	Baseline through Week 16

Secondary

Measure	Time frame
Percentage of participants with improvement of AD	Baseline through Week 16
Percentage of participants with TEAEs	Baseline through Week 36
Serum concentration of TRIV-573	Baseline through Week 36
Percentage of participants with anti-TRIV-573 antibodies	Baseline through Week 36

Contacts

CONTACTTriveni Bio, Inc

clinicaltrials@triveni.bio+1 (781) 472-2230

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 25, 2026